Johnson & Johnson: Depressive Disorder, Major trials

The registry lists 58 Depressive Disorder, Major studies with Johnson & Johnson as lead sponsor. 5 are open to participants now and 25 have results posted.

Early Phase 1 1Phase 1 7Phase 2 16Phase 3 23Phase 4 4No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderNot yet recruitingNCT07747389Phase 3
• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderRecruitingNCT07573176Phase 3
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderRecruitingNCT07227454Phase 3
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsRecruitingNCT06559306Phase 3
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderRecruitingNCT05850689Phase 3
• A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and PleasureTerminatedNCT06635135Phase 3Results posted
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyCompletedNCT05550532Phase 3Results posted
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)TerminatedNCT05518149Phase 3Results posted
• A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyCompletedNCT05455684Phase 3Results posted
• An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT05061719Phase 3Results posted
• Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT05061706Phase 3Results posted
• Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT04985942Phase 3Results posted
• A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray TreatmentCompletedNCT04829318Phase 4Results posted
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With SeltorexantCompletedNCT04533529Phase 3Results posted
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyTerminatedNCT04532749Phase 3Results posted
• A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive DisorderCompletedNCT04338321Phase 3Results posted
• Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderCompletedNCT04285515Phase 3Results posted
• A Study of JNJ-61393215 in the Treatment of DepressionCompletedNCT04080752Phase 2Results posted
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of DepressionCompletedNCT03559192Phase 2Results posted
• A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyCompletedNCT03321526Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyCompletedNCT03227224Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideCompletedNCT03185819Phase 2Results posted
• 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideCompletedNCT03097133Phase 3Results posted
• 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideCompletedNCT03039192Phase 3Results posted
• An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious DistressCompletedNCT02498392Phase 2Results posted
• An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive DisorderCompletedNCT02473289Phase 2Results posted
• A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideCompletedNCT02133001Phase 2Results posted
• A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive DisorderTerminatedNCT01957410Phase 2Results posted
• A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety SymptomCompletedNCT01870843Phase 4Results posted
• A Study of Ketamine in Patients With Treatment-resistant DepressionCompletedNCT01627782Phase 2Results posted
• A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)CompletedNCT07258485
• A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderCompletedNCT06785012Phase 2
• A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With AticaprantTerminatedNCT06514742Phase 3
• A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)CompletedNCT05841030
• A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor AntidepressantTerminatedNCT05109195
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and PsychotherapyTerminatedNCT04951609Phase 1
• A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric EmergencyWithdrawnNCT04829669
• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyCompletedNCT04513912Phase 3
• A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in ItalyCompletedNCT04463108
• A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive DisorderCompletedNCT04451187Phase 1
• A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive DisorderCompletedNCT03374475Phase 1
• Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)CompletedNCT03014544
• A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive DisorderCompletedNCT02919579Phase 1
• A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive DisorderCompletedNCT02902601Phase 1
• Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)CompletedNCT02489305
• A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive DisorderCompletedNCT02476058Phase 1
• A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With AntidepressantsCompletedNCT02067299Phase 1
• An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety SymptomsCompletedNCT01814098Phase 4
• A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe DepressionCompletedNCT01814085Phase 4
• A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant DepressionCompletedNCT01640080Phase 2
• A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety SymptomsCompletedNCT01582815Phase 2
• Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder PatientsCompletedNCT01533285Early Phase 1
• A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive DisorderTerminatedNCT01114698Phase 2
• A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe DepressionCompletedNCT00566202Phase 2
• CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.CompletedNCT00246233Phase 3
• Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard TherapyCompletedNCT00095134Phase 3
• A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive DisorderCompletedNCT00073203Phase 2
• A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant DepressionCompletedNCT00044681Phase 3